FDA sets Sept. 23 adcomm to review Grail's Galleri cancer test, which missed the primary endpoint of a 142,000-person UK trial.
The Grail booth at the ASCO 2026 meeting. (Karen Weintraub / Endpoints News)
August 7, 2026 12:08 PM EDT
FDA to hold adcomm for Grail cancer test that failed in large, randomized trial
The FDA will host an advisory committee meeting in September to review Grail’s controversial cancer test that failed to meet the primary endpoint of a …
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
The FDA's advisory committee will meet on September 23 to review the PMA application for GRAIL's Galleri multi-cancer early…
An oncologist shares three lessons from the world’s first randomized trial on a multi-cancer early detection.
GRAIL Reports Full Results From NHS-Galleri Trial Demonstrating Substantial Reduction in Stage IV Cancer Diagnoses at 2026 ASCO…
GRAIL Presents PATHFINDER 2 Results of More Than 35,000 Participants Showing the Galleri® Test Substantially Increased Cancer…
The FDA has delayed a decision on the approval of AstraZene | The FDA has delayed a decision on the approval of AstraZeneca’s…
China reins in its biotech innovation engine, radiopharma boom meets unexpected hurdles, and more news from The Readout
FDA approves another blood test for colon cancer screening
